Shares of pharmaceutical companies fell across Europe and Asia after President Donald Trump said he planned to order a cut in ...

Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse ...

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

The president is planning Monday to revive a plan from his first term, which would peg the prices the United States pays for ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

Kroger, Albertsons and others allege an unlawful monopoly in one legal case and aim to recover overcharges for a drug in ...

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO ...

Takeda will host an investor call on Sunday ... but it is to illustrate that as a global innovative pharmaceutical company, we have a very strong presence in the U.S., which is, by far today ...

By Rachel Cohrs Zhang, Derek Wallbank, and Hadriana Lowenkron President Donald Trump said he plans to order a cut in US ...

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Takeda Pharmaceutical Co. imply an improvement in the company's underlying business. Investors should show ...

Takeda Pharmaceutical Co. Currently has a Zacks ... the components of the Momentum Style Score for TAK that show why this company shows promise as a solid momentum pick. Looking at a stock's ...

The lawsuits pertain to the drug Dexilant, used to treat acid reflux, and Copaxone, an injectable drug that treats a type of ...